🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Eteplirsen

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 3 small molecule active

    2 trials

  2. Etoposide

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  3. Etoposide

    The First People's Hospital of Lianyungang

    Non-Hodgkin's Lymphoma

    phase 3 small molecule active

    1 trial

  4. Everolimus

    United Therapeutics Europe Ltd

    Pediatric Heart Transplantation

    phase 3 small molecule active

    1 trial

  5. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  6. Evolocumab

    Amgen

    Coronary Heart Disease (CHD)

    phase 3 small molecule completed

    1 trial

  7. Exoskeletal assisted walking

    United Therapeutics Europe Ltd

    Spinal Cord Injuries

    phase 3 other active

    1 trial

  8. Experimental: Venetoclax in combination with Decitabine (+-sorafenib)

    Kunming Hope of Health Hospital

    Elderly AML Patients

    phase 3 other active

    1 trial

  9. Expressive Writing

    United Therapeutics Europe Ltd

    Posttraumatic Stress Disorder

    phase 3 other completed

    1 trial

  10. Extensively Hydrolyzed formula

    United Therapeutics Europe Ltd

    Cow Milk Allergy

    phase 3 other completed

    1 trial

  11. FAT EMULSIONS , Triheptanoin

    Lacuna Pharma Pty Ltd

    Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    phase 3 small molecule active

    1 trial

  12. FEIBA

    Takeda

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  13. FF/UMEC/VI

    Grace Therapeutics

    Asthma

    phase 3 small molecule active

    1 trial

  14. FKB238 (bevacizumab)

    Centus Biotherapeutics Europe Limited

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  15. FLORTAUCIPIR (18F), FLORTAUCIPIR (18F), FLORBETAPIR (18F), FLORBETAPIR (18F)

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  16. FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%

    The George Institute

    Patients with hip or knee infections

    phase 3 small molecule active

    1 trial

  17. FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA

    Fondazione Telethon ETS

    Higher-risk-myelodysplastic syndromes

    phase 3 small molecule active

    1 trial

  18. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit Therapeutics

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  19. FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN

    The George Institute

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  20. FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  21. FMX-101, 4% minocycline foam

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    2 trials

  22. FMX101

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  23. FMX101

    Cutia Therapeutics (Shanghai) Co., Ltd

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  24. FMX103 1.5%

    VYNE Therapeutics

    Papulopustular Rosacea

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources